

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2024-07-25** | Period of Report: **2024-07-24**  
SEC Accession No. [0001493152-24-029022](#)

[\(HTML Version on secdatabase.com\)](#)

FILER

**Sharps Technology Inc.**

CIK: **1737995** | IRS No.: **823751728** | State of Incorporation: **NV** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **001-41355** | Film No.: **241139946**  
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address  
105 MAXESS ROAD  
STE. 124  
MELVILLE NY 11747

Business Address  
105 MAXESS ROAD  
STE. 124  
MELVILLE NY 11747  
(631) 574-4436

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): July 24, 2024

**Sharps Technology, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Nevada**

(State or Other Jurisdiction of Incorporation)

**001-41355**

(Commission  
File Number)

**82-3751728**

(IRS Employer  
Identification No.)

**105 Maxess Road, Melville, New York 11747**

(Address of Principal Executive Offices)

**(631) 574 -4436**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value	STSS	NASDAQ Capital Market
Common Stock Purchase Warrants	STSSW	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

### Item 1.01 Entry into a Material Definitive Agreement.

On July 24, 2024, Sharps Technology, Inc., a Nevada corporation (the “Company”), entered into a Supply Agreement (the “Supply Agreement”) with Stericore Solutions, LLC, a Texas limited liability company, (“Stericore”), pursuant to which Stericore agreed to purchase 520 million units of 10ml PP Sologard syringes from the Company. The specific purchase price is confidential and redacted from the Supply Agreement filed herewith but revenues are expected in excess of \$50M. Pursuant to the Supply Agreement, Stericore has agreed to purchase 520 million units of 10ml PP Sologard syringes in the following increments: 40 million units in the first year, and 120 million units every year for the remaining life of the Supply Agreement. The Supply Agreement has a five (5) year term commencing upon the initial delivery of product to the point of entry in USA, targeted for November 1, 2024 (the “Initial Term”). Upon expiration of the Initial Term, the Supply Agreement will automatically renew for additional one (1) year periods (each, a “Renewal Term”), unless a party gives the other party written notice of termination at least ninety (90) days prior to the end of the Initial Term or Renewal Term. The Agreement may be terminated by either party upon written notice to the other party if the other party breaches any material term or condition of this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice thereof. The Agreement may be terminated by either party upon written notice to the other party if the other party becomes insolvent, makes an assignment for the benefit of creditors, or a petition under any bankruptcy or insolvency Law is filed by or against such party and is not dismissed within 120 days. If either party is acquired by a competitor of the other party, then either party can terminate the Agreement with six (6) months written notice.

The foregoing is a summary description of certain terms of the Supply Agreement. For a full description of all terms, please refer to the copy of the Supply Agreement that is incorporated by reference and filed herewith as [Exhibit 1.0](#).

### Item 7.01 Regulation FD Disclosure

On July 25, 2024, Sharps Technology, Inc. (the “Company”) issued a press release announcing that it has entered into a five-year agreement with Stericore Solutions, LLC to supply them with customized 10mL SoloGard syringes, thus selling out the available manufacturing capacity for the 10mL SoloGard disposable syringe in the Company’s EU facility.

A copy of the press release is furnished hereto as [Exhibit 99.1](#) and incorporated herein by reference.

### Exhibits 9.01 Financial Statements and Exhibits

<b>Exhibit No.</b>	<b>Description</b>
10.1	<a href="#">Supply Agreement, dated July 24, 2024, by and among Sharps Technology, Inc. and Stericore Solutions, LLC</a>
99.1	<a href="#">Press Release dated July 25, 2024</a>
104	Cover Page Interactive Data File (embedded with the Inline XBRL document)

---

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 25, 2024

**SHARPS TECHNOLOGY, INC.**

*/s/ Robert Hayes*

---

Robert Hayes

Chief Executive Officer

---

## Stericare Solutions and Sharps Technology, Inc. Supply Agreement

This Supply Agreement (“Agreement”) is entered into on July 24<sup>th</sup>, 2024, by and between Sharps Technology, Inc., a Nevada corporation (“Seller”), and Stericare Solutions, LLC a Texas limited liability company (“Buyer”), having an address of 4409 Haltom Road, Haltom City, TX 76117. Seller manufactures and sells syringe formats, and Buyer wishes to purchase certain Goods (as defined below) from Seller. The Buyer and Seller are referred to individually as a “Party” and collectively as “Parties”.

### 1.0 Definitions

- “Action” means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature.
- “Basic Purchase Order Terms” means the terms specified by Buyer in a Purchase Order: (a) a list of the Goods to be purchased; (b) the quantity of each of the Goods ordered; (c) the Requested Delivery Date; (d) the unit Price for each of the Goods to be purchased; (e) the billing address; and (f) the Delivery Location.
- “Business Day” means any day except Saturday, Sunday or any other day on which commercial banks located in Columbia, South Carolina, are authorized or required by Law to be closed for business.
- “Defective” means not conforming to the Product Warranty under Section 8.0.
- “Defective Goods” means goods shipped by Seller to Buyer pursuant to this Agreement that are Defective.
- “Delivery Location” means the street address within the Territory for delivery of the Goods specified in the applicable Purchase Order.
- “Disclosing Party” has the meaning set forth in Section 10.0.
- “Effective Date” means the date first set forth above.
- “Forecast” means, with respect to any six-month period, a good faith projection or estimate of Buyer’s requirements for Goods during each month during the period.
- “Goods” means the goods identified on Schedule 1 and described in the Specifications.
- “Governmental Authority” means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority, or any arbitrator, court or tribunal of competent jurisdiction.
- “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, award or determination entered by or with any Governmental Authority.
- “Initial Term” has the meaning set forth in Section 2.0.
- “Inspection Period” has the meaning set forth in Section 8.0.

- 
- “Intellectual Property Rights” means all industrial and other intellectual property rights comprising or relating to: (a) Patents; (b) Trademarks; (c) internet domain names, whether or not Trademarks, registered by any authorized private registrar or Governmental Authority, web addresses, web pages, website and URLs; (d) works of authorship, expressions, designs and design registrations, whether or not copyrightable, including copyrights and copyrightable works, software and firmware, data, data files, and databases and other specifications and documentation; (e) Trade Secrets; and (f) all industrial and other intellectual property rights, and all rights, interests and protections that are associated with, equivalent or similar to, or required for the exercise of, any of the foregoing.
  - “Law” means any statute, law, ordinance, regulation, rule, code, constitution, treaty, common law, Governmental Order or other requirement or rule of law of any Governmental Authority.
  - “Losses” has the meaning set forth in Section 9.0.
  - “Nonconforming Goods” means any goods received by Buyer from Seller pursuant to a Purchase Order that: (a) do not conform to the [make/model number/UPC/SKU/[PRODUCT IDENTIFIER]] listed in the applicable Purchase Order; (b) do not fully conform to the Specifications; or (c) materially exceed the quantity of Goods ordered by Buyer pursuant to this Agreement or any Purchase Order.
  - “Party” has the meaning set forth in the preamble to this Agreement.
  - “Payment Failure” has the meaning set forth in Section 5.0.
  - “Person” means any individual, partnership, corporation, trust, limited liability entity, unincorporated organization, association, Governmental Authority or any other entity.

- “Personnel” of a Party means any agents, employees, contractors or subcontractors engaged or appointed by such Party.
- “Price” has the meaning set forth in Section 5.0.
- “Product Warranty” has the meaning set forth in Section 8.0.
- “Quality Agreement” has the meaning set forth in Section 7.0.
- “Receiving Party” has the meaning set forth in Section 10.
- “Release” means a document issued by Buyer to Seller pursuant to a Purchase Order that identifies the quantities of Goods constituting Buyer’s requirements and the Delivery Locations and Requested Delivery Dates for such Goods.
- “Renewal Term” has the meaning set forth in Section 2.0.
- “Representatives” means a Party’s Affiliates and each of their respective Personnel, officers, directors, partners, shareholders, attorneys, third-party advisors, successors and permitted assigns.
- “Seller” has the meaning set forth in the preamble to this Agreement.
- “Seller Contracts” means all contracts or agreements to which Seller is a party or to which any of its material assets are bound.
- “Seller’s Intellectual Property Rights” means all Intellectual Property Rights owned by or licensed to Seller.
- “Specifications” means the specifications for the Goods attached hereto as Exhibit A.
- “Taxes” means any and all present and future sales, income, stamp and other taxes, levies, imposts, duties, deductions, charges, fees or other taxes imposed on, in respect of or in connection with the sale, purchase, delivery, storage, use or transportation of Goods or the performance of Services.

## **2.0 Term and Termination**

- a) The Agreement will commence immediately upon signature and will expire five years from the initial delivery of product to the point of entry in USA, targeted for November 1, 2024 (the “Initial Term”).  
Upon expiration of the Initial Term, the Agreement will automatically renew for additional one (1) year periods (each, a
- b) “Renewal Term”), unless a Party gives the other Party written notice of termination at least ninety (90) days prior to the end of the Initial Term or Renewal Term.
- c) The Agreement may be terminated by either Party upon written notice to the other Party if the other Party breaches any material term or condition of this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice thereof.  
The Agreement may be terminated by either Party upon written notice to the other Party if the other Party becomes insolvent,
- d) makes an assignment for the benefit of creditors, or a petition under any bankruptcy or insolvency Law is filed by or against such Party and is not dismissed within 120 days.
- e) If either Party is acquired by a competitor of the other Party, either Party can terminate the Agreement with six (6) months written notice.

## **3.0 Purchase and Sale of Goods**

- a) Buyer agrees to purchase from Seller, and Seller agrees to sell to Buyer, the Goods specified in the Specifications.
- b) Buyer will issue Purchase Orders to Seller specifying the Goods to be purchased, including [make/model number/UPC/SKU/[PRODUCT IDENTIFIER]], quantity, Requested Delivery Date, unit Price, billing address, and Delivery Location.
- c) Buyer will provide a six-month rolling forecast detailing the anticipated requirements of all goods.
- d) Seller will deliver the Goods to Buyer at the Delivery Location specified in the applicable Purchase Order on the Requested Delivery Date.
- e) Buyer will inspect the Goods delivered by Seller pursuant to this Agreement within 30 days after such delivery (the “Inspection Period”).
- f) Buyer may reject any Nonconforming Goods and, at Buyer’s election, return such Nonconforming Goods to Seller for a full refund or require Seller to replace such Nonconforming Goods with conforming Goods.  
Product or process changes which would cause any Good to deviate in any way from the Specifications shall not be made without the express prior written consent of Buyer. Specifications may otherwise be revised from time to time as mutually agreed
- g) in writing between Buyer and Seller (either by execution of an amended Exhibit A and/or Exhibit B that references the new revision level or by other writings duly authorized between the Parties).

## **4.0 Volume Commitment**

- Sharps Technology agrees to supply and Stericare agrees to purchase 80% of Stericare's demand, limited by the capacity of
- a) Sharps as outlined below. Existing demand for Stericare product estimates this requirement at 520 Million units over the life of the initial agreement.
  - b) **Sharps Anticipated Monthly Capacity**
    - a. November 2024 - April 2025 2 Million units per month
    - b. April 2025 - September 2025 4 Million units per month
    - c. September 2025 - 20 Million units per month
  - c) **Targeted Annual (12 month) Volumes:**
    - a. Year 1 40 Million units
    - b. Years 2-5 120 Million units

## **5.0 Price and Payment**

- a) The price of the Goods sold under this Agreement will be as set forth in the Purchase Order (the "Price"). Initial prices are described in Attachment 1.
- b) All amounts payable by Buyer to Seller under this Agreement will be paid in US dollars by ACH wire or similar means.
- c) **Payment terms:** 1% ten, net 30 days.
- d) If Buyer fails to make any payment when due ("Payment Failure"), Buyer will pay interest on the delinquent amount at a rate of ten% per annum from the date such payment was due until paid in full.  
Pricing is based on the raw material costs paid by Sharps as of July 1, 2024. (PP-\$xxxpound) Any increase in raw material
- e) pricing will be passed through to Stericare on an annual basis, based on the material content of the syringe as detailed in Schedule 1.  
Pricing may be adjusted within the year should any critical component of the cost structure have a dynamic change impacting
- f) the cost of the product by 10% or greater. Such request for adjustment will be submitted by Sharps with qualified invoice or cost details to suffice Stericare.

## **6.0 Shipping and Production:**

- Initial production will be at Sharps Hungary manufacturing facility. Additional volume may be provided from sister facility in Italy or from Sharps NA facility in Columbia SC. Any product imported to NA will be priced as CIF point of entry. Any product coming from Columbia SC will be priced as FOB point of manufacture. The parties will work together to minimize all logistics costs.
- a)

---

## **7.0 Quality**

- Seller warrants that any Goods sold to Buyer hereunder shall comply in all respects with the Specifications therefore and shall be free from defects in design, product and workmanship, and that, at all times, Seller will comply with the terms and provisions
- a) of an agreed Supplier Quality Agreement between Buyer and Seller, which shall be executed by the Parties within thirty (30) days after the Effective Date and shall remain in effect according to its terms during the Term of this Agreement (the "Quality Agreement").

## **8.0 Product Warranty**

- a) Seller warrants that all Goods delivered by Seller pursuant to this Agreement will conform to the Specifications and be free from material defects in material and workmanship.
- b) Buyer will inspect the Goods delivered by Seller pursuant to this Agreement within the Inspection Period and will have the right to reject any Nonconforming Goods.
- c) If Buyer rejects any Goods pursuant to this Section 8 at Buyer's election, Seller will either replace such Goods with conforming Goods or refund the Price for such Goods.

## **9.0 Indemnification**

- a) Each Party hereto shall defend, indemnify, and hold harmless the other Party, and such other party's respective directors, officers, shareholders, employees and agents (collectively, "Indemnitees") from and against all claims, demands, actions, liabilities, losses, damages and expenses (including reasonable attorneys' fees) (collectively, "Claims") to the extent arising out of or

resulting from any breach by such Party of its respective covenants, representations and warranties hereunder, provided that such Party shall have no responsibility to defend, indemnify and hold harmless Indemnitees for that portion of any Claims arising out of or resulting from the gross negligence or willful misconduct of such Indemnitees.

Seller will indemnify and hold Buyer and its Indemnitees harmless from any against all Claims which are brought against Buyer or its Indemnitees, including Claims by third parties, to the extent relating to, resulting from or arising out of: (i) infringement or misappropriation of intellectual property rights by the technology, processes, know-how, and other intellectual property used by Seller to manufacture the Goods; or (ii) Seller's negligence, misconduct, or violation of applicable laws.

- b) Buyer will indemnify, defend and hold harmless Seller and Seller's Indemnitees from and against any and all Losses incurred by such Persons arising out of or in connection with any Claim that the Goods infringe or misappropriate the Intellectual Property Rights of any third party to the extent caused by the Specifications or other requirements furnished by Buyer.

Each Party shall maintain general comprehensive liability insurance covering each occurrence of bodily injury and property damage in the amount of not less than three million US dollars (\$3,000,000 US) combined single limit with endorsements for: (i) Goods and completed operations; and (ii) blanket contractual liability (deleting any exclusion from Goods and completed operations liability).

- d) Seller agrees to promptly notify Buyer upon the occurrence of any event of loss (including the commencement of any action against an indemnified party) in respect of which indemnity or reimbursement may be sought under this Agreement.
- e) Notwithstanding anything in this Agreement to the contrary, in no event will Buyer be liable to Seller for any amount in excess of the limits paid by Buyer's insurance carrier under the applicable insurance coverage under this Agreement.

- 
- g) Notwithstanding anything in this Agreement to the contrary, in no event will Seller be liable to Buyer for any amount in excess of the limits paid by Seller's insurance carrier under the applicable insurance coverage under this Agreement.

No Consequential Damages. EXCEPT FOR A PARTY'S INDEMNIFICATION OR BREACH OF CONFIDENTIALITY OBLIGATIONS HEREIN, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS OR REVENUE, OR CLAIMS OF THIRD PARTIES FOR SUCH DAMAGES REGARDLESS OF WHETHER A PARTY MAY HAVE HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS.

- h)

## **10.0 Confidential Information**

- a) All Confidential Information disclosed by one Party to the other Party pursuant to this Agreement will be kept confidential by the Receiving Party.
- b) The Receiving Party will not disclose any Confidential Information of the Disclosing Party to any third party without the prior written consent of the Disclosing Party.
- c) The Receiving Party will use the Confidential Information of the Disclosing Party solely for the purpose of performing its obligations under this Agreement.

## **11.0 Dispute Resolution**

- a) Any Dispute arising out of or in connection with this Agreement will be resolved through binding arbitration in accordance with the rules of the American Arbitration Association.
- b) The arbitration will be conducted by a single arbitrator in New York, NY.
- c) The arbitrator will have the authority to grant any legal or equitable remedy or relief that such arbitrator deems just and proper.
- d) The Parties agree that the award of the arbitrator will be final and binding upon the Parties and that judgment upon the award may be entered in any court of competent jurisdiction.

## **12.0 Transferability**

- a) The agreement will continue in its entirety should ownership change with either company.

## **13.0 Governing Law**

- a) This Agreement will be governed by and construed in accordance with the Laws of the State of New York, without giving effect to any choice or conflict of Law provision or rule.



Any Action arising out of or in connection with this Agreement must be instituted solely in the federal or state courts located in New York County, State of New York and the Parties irrevocably submit to the exclusive jurisdiction of such courts in any such Action.

---

#### 14.0 Entire Agreement: Waivers

- This Agreement constitutes the entire agreement between the Parties with respect to the supply of the Goods and all prior understanding between the Parties, whether written or oral, relating to the Goods are superseded by this Agreement. To the extent there is any overlap between this Agreement, the Quality Agreement and any other agreement or understanding between the Parties, this Agreement shall govern as to all matters except those relating expressly to quality assurance activities under the Quality Agreement. None of the terms of this Agreement shall be deemed to be waived, modified or amended by either Party unless such a waiver, modification or amendment specifically references this Agreement and is in writing signed by duly authorized representatives of both Parties. Any failure by any Party hereto to enforce at any time any provision under this Agreement shall not be considered a waiver of that Party's right thereafter to enforce each and every provision of this Agreement.
- a) No amendment or modification of any provision of this Agreement will be effective unless in writing signed by both Parties.
  - b) If any provision of this Agreement shall be held or made invalid by a court decision, statute or rule, or shall be otherwise rendered invalid, the remainder of this Agreement shall not be affected thereby.

---

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.

#### Sharps Technology, Inc.

By: /s/ Robert Hayes Date: 7-24-2024

Name: Robert Hayes

Title: Chief Executive Officer

#### Stericare Solutions LLC

By: /s/ Tom Star Date: 7-24-2024

Name: Tom Star

Title: CEO of Stericare Solutions LLC

---

### Schedule 1 Pricing and Raw Material Pass Through

10ml PP Sologard syringes, including cap Price per thousand \$xxxx

**Raw material cost pass through:** Pricing is based on the raw material costs paid by Sharp's as of July 1, 2024. (PP-\$xxx/pound) Any increase in raw material pricing will be passed through to Stericare on an annual basis, based on the material content of the syringe as detailed below.

	Gram	Material
Barrel-	x	PP

Plunger-	x	PP
Piston-	x	TPE
Cap-	x	PP

The price of raw materials will be reviewed on an annual basis with any net increase of x cents per pound or greater from the last material adjustment, initiating an price modification.

For each x cents per pound increase in PP, the product price will increase \$xxx/thousand.

For each x cents per pound increase in TPE or Rubber, the product price will increase xxx

---

**Exhibit A**  
**Buyers Specifications**

---

Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +\$50 Million in New Revenue for EU Facility

*Definitive agreement sells out the 10mL SoloGard production capacity at Sharps' manufacturing site in the EU and drives expansion to support the project's growth in the future*

*Sharps' portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes*

*Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter*

NEW YORK, July 25, 2024, Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps' facility in the EU. The customer initiated an evaluation of Sharps' SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.

"Creating a strategic partnership with the customer and selling out production capacity at the Hungary plant for the next five years is an historic accomplishment for Sharps and the future success of the Company," stated Robert Hayes, CEO of Sharps Technology. "The collaboration creates a five-year sales agreement for at least 500 million syringes and essentially consumes the current available manufacturing capacity for Sharps' 10mL SoloGard disposable syringe. This project also provides a clear path for near-term revenue for our company beginning in Q4 2024, with a phased ramp up into 2025."

Filippo Filippi, General Manager of the SafeGard manufacturing facility is pleased that his plant is delivering on commitments made by Sharps leadership in 2022. "We have been driven to bring our innovative syringes to the U.S. healthcare market," says Filippi. "After two years of dedicated efforts, I am excited for this five-year commitment for the 500 million units, starting with the 10mL SoloGard shipments in November of this year. Equally as important, this sales agreement will help provide a solid foundation for the continued expansion of Sharps' European division in Hungary."

---

The Company believes that the need for innovative injection solutions continues to grow rapidly as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. As a result of this market growth and the impact of the tariffs, recalls, and quality issues with Chinese supplied syringes, Sharps is seeing increasing levels of interest and potential demand for its high-quality smart safety syringe products. Specializing in the development and manufacturing of innovative drug delivery systems, Sharps' SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features, as well as World Health Organization accredited re-use prevention measures.

### **About Sharps Technology**

Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and is partnering with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For more information about Sharps Technology, please visit the website at: <http://sharpstechnology.com>.

### **FORWARD-LOOKING STATEMENTS:**

This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Investor Relations:

Dave Gentry

RedChip Companies, Inc.

1-800-RED-CHIP (733-2447)

Or 407-644-4256

STSS@redchip.com

---

**Cover****Jul. 24, 2024**

<a href="#">Document Type</a>	8-K
<a href="#">Amendment Flag</a>	false
<a href="#">Document Period End Date</a>	Jul. 24, 2024
<a href="#">Entity File Number</a>	001-41355
<a href="#">Entity Registrant Name</a>	Sharps Technology, Inc.
<a href="#">Entity Central Index Key</a>	0001737995
<a href="#">Entity Tax Identification Number</a>	82-3751728
<a href="#">Entity Incorporation, State or Country Code</a>	NV
<a href="#">Entity Address, Address Line One</a>	105 Maxess Road
<a href="#">Entity Address, City or Town</a>	Melville
<a href="#">Entity Address, State or Province</a>	NY
<a href="#">Entity Address, Postal Zip Code</a>	11747
<a href="#">City Area Code</a>	631
<a href="#">Local Phone Number</a>	574 -4436
<a href="#">Written Communications</a>	false
<a href="#">Soliciting Material</a>	false
<a href="#">Pre-commencement Tender Offer</a>	false
<a href="#">Pre-commencement Issuer Tender Offer</a>	false
<a href="#">Entity Emerging Growth Company</a>	true
<a href="#">Elected Not To Use the Extended Transition Period</a>	false
<a href="#">Common Stock, \$0.0001 par value</a>	
<a href="#">Title of 12(b) Security</a>	Common Stock, \$0.0001 par value
<a href="#">Trading Symbol</a>	STSS
<a href="#">Security Exchange Name</a>	NASDAQ
<a href="#">Common Stock Purchase Warrants</a>	
<a href="#">Title of 12(b) Security</a>	Common Stock Purchase Warrants
<a href="#">Trading Symbol</a>	STSSW
<a href="#">Security Exchange Name</a>	NASDAQ





"Business" - The registrant involved in bankruptcy proceedings during the preceding five years, the value the indicates that the registrant has filed all documents and reports required to be filed by Section 13, 15 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value the indicates the registrant has not. Registrant not involved in bankruptcy proceedings during the preceding five years should not report this element."

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000





